tirzepatide is ozempic Ozempic, other GLP-1 weight loss drugs linked to hair loss What Happens When You Switch

SURMOUNT-5 data (2025) shows tirzepatide achieves approximately 47% greater weight loss than semaglutide overall, suggesting stronger average appetite control

Eli Lilly says that Zepbound is a dual receptor agonist that targets both GIP and GLP-1 receptors, unlike other incretins approved for obesity management, which target only GLP-1 receptors. And Novo Nordisk says that Wegovy has the broadest GLP-1 label, including indications for reducing risk of major adverse cardiovascular events in some patients and for treatment of a certain liver condition in some adults

It adds that GLP-1 use may lower this figure, and that glucose instability disqualifies donors regardless of the absolute number

1 Table 1 Comparison of Peptide and Small Molecule GLP-1 Receptor Agonists GLP-1, glucagon-like peptide-1

High fevers are also dangerous